罗全勇. MIBG及其衍生物的研究进展[J]. 国外医学？放射医学核医学分册,2002，26：216-219.Luo Quanyong. The recent research progress of MIBG and its derivatives[J]. Foreign Med Sci Sec Radiat Med Nucl Med, 2002, 26: 216-219（in Chinese）.
[2]
Wafelman A R, Konings MCP, Hoefnagel C A, et al. Synthesis, radiolabelling, and stability of radioiodinated m-iodobenzylguanidine, a review[J]. Appl Radiat Isot, 1994, 45: 997-1007.
[3]
Vaidyanathan G and Zalutsky M. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation[J]. Nucl Med Biol, 1995, 22: 61-64.
[4]
Samnick S, Bader J B, Müller M, et al. Improved labelling of no-carrier-added123I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias[J]. Nucl Med Commun, 1999, 20: 537-545.
[5]
Owens J, Bolster A A, Prosser J E, et al. No-carrier-added123I-MIBG: an initial clinical study in patients with phaeochromocytoma[J]. Nucl Med Commun, 2000, 21: 437-440.
[6]
Knickmeier M, Mathejia P, Wichter T, et al. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy[J]. Eur J Nucl Med, 2000, 27: 302-307.
[7]
Knickmeier M, Schafers M and Schober O.Two years’ experience using no-carrier-added meta-[123I]iodobenzylguanidine in clinical studies[J]. Eur J Nucl Med, 2001, 28: 941.
[8]
Verberne H J, Bruin K, Habraken J B A, et al. No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity[J]. Eur J Nucl Med Mol Imaging, 2006, 33: 483-490.
[9]
Barrett J A, Loyal J L, Hillier S M, et al. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier added 123/131I-MIBG on efficacy, pharmacokinetics , and tissue distribution[J]. Cancer Biother Radiopharma, 2010, 25: 299-308.
[10]
Coleman R E, Goldsmith S J, Noto R B, et al. One Year Follow-Up for the Phase I MTD Study of Ultratrace Iobenguane I-131 in Patients with Malignant Pheochromocytoma/Paraganglioma (Pheo)[J]. Abstracts Presented at the 2nd Annual Meeting of the North American Neuroendocrine Tumor Society, Pancreas, 2010, 39: 272.
[11]
Matthay K K, Weiss B D, Villablanca J, et al. Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131(nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study[J]. J Clin Oncol (Meeting Abstracts), 2011, 29: suppl 9512.
[12]
Pryma D A, Barrett J A, Coleman R E, et al. Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane(nca-MIBG) in patients with malignant pheochromocytoma (Pheo)[J]. J Clin Oncol (Meeting Abstracts), 2011, 29: suppl e21122.
[13]
Chin B B, Kronauge J F, Femia F J, et al. Phase-1 clinical trial results of high-specific-activity carrier-free123I-iobenguane[J]. J Nucl Med, 2014, 55: 765771.
[14]
Vaidyanathan G, Zalutsky M. No-carrier-added synthesis of meta-[131I]iodobenzyl guanidine[J]. Appl Radiat Isot, 1993, 44: 621-628.
He Y, Das B, Baruchel S, et al. Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage[J]. Nucl Med Commun, 2004, 25: 1125-1130.
[17]
Hunter D H, Goel A, Flanagan R J. Process for the preparation of radiolabeled meta-halobenzylguanidine: EP, 0693476[P]. 1996-4.
[18]
Donovan A, Forbes J, Dorff P, et al. A new strategy for preparing molecular imaging and therapy agents using fluorine-rich (fluorous) soluble supports[J]. J Am Chem Soc, 2006, 128: 3536-3537.
[19]
Vaidyanathan G, Affleck J D, Alstonk L, et al. A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [211At]MABG[J]. J Label Compd Radiopharm, 2007, 50: 177-182.
[20]
Donovan A C and Valliant J F. A convenient solution-phase method for the preparation of meta-iodobenzylguanidine in high effective specific activity[J]. Nucl Med Biol, 2008, 345: 741-746.
[21]
Dzandzi J P, Vera D R, Valliant J F. A hybrid solid-fluorous phase radioiodination and purification platform[J]. J Labelled Comp Radiopharm, 2014, 57: 551-557.
[22]
Hu B, Blecha J, Neumann K, et al. A new efficient synthesis of no carrier added radioiodinated tracers[J]. J Nucl Med, 2014, 55(Suppl 1): 1181.
